ClinicalTrials.gg
Not yet recruitingNCT06954818Updated May 8, 2025

Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

A Phase 1 interventional study of A zoster mRNA vaccine SYS6017 and Placebo in Herpes Zoster, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.

02

Conditions studied

  • Herpes Zoster

Browse trials for

03

In context

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

This study's planned enrollment of 200 is above the median of 160 across 248 interventional studies indexed under Herpes Zoster.

Browse Herpes Zoster studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 43 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Healthy participants aged 40 years or more;
  • 2. Be able to understand the study procedures and comply with the requirements of the protocol for the scheduled visits, voluntarily consent to participate in the study and sign the form (ICF);
  • 3. Being in good health at the discretion of investigators based on medical history inquiry, physical examination, laboratory test and electrocardiograph examination;
  • 4. For female participants of : no sexual activity or used effective methods within one menstrual cycle before enrollment; no pregnancy plans and agree to used effective contraceptive methods with 8 months after enrollment.

Exclusion criteria

Exclusion Criteria:

  • 1. History of zoster;
  • 2. History of vaccination with varicella vaccine or zoster vaccine (including vaccine);
  • 3. Axillary temperature ≥ 37.1℃ on the day of enrollment or within 24 h before enrollment;
  • 4. Have abnormal test or examination result that is of Grade 1 (inclusive) or more in accordance with the Guidelines for Adverse Event Grading Standards for Clinical Trials of Preventive Vaccines (2019) issued by China National Medical Products Administration or other applicable adverse event grading standards referred in the protocol;
  • 5. History of allergy to any component of the investigational vaccine, or history of severe allergic reaction (including but not limited to anaphylaxis, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenia purpura or Arthus reaction) to vaccines or medicines;
  • 6. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that would increase the risk of myocarditis or pericarditis;
  • 7. History of demyelinating diseases, including but not limited to Guillain-Barré syndrome, multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis, etc.
  • 8. Current epilepsy or convulsion, severe neurological or psychiatric disorders;
  • 9. Have to intramuscular injection, e.g., diagnosed thrombocytopenia, any coagulation disorders, or current treatment with anticoagulants, etc;
  • 10. Active malignant tumor, malignant tumor without adequate treatment, malignant tumor with a potential risk of recurrence during the study;
  • 11. Active, unstable, severe or uncontrolled cardiovascular and cerebrovascular diseases, thrombotic diseases, blood and lymphatic system diseases, liver and kidney diseases, respiratory diseases, metabolic diseases, musculoskeletal diseases, diseases, etc;
  • 12. Have diagnosed immunocompromise or , congenital or functional asplenia, or splenectomy;
  • 13. Have received immunosuppressants, immunostimulants, or other immunomodulatory medicines (e.g., , ≥ 20 mg/d prednisone or equivalent) for a long time (defined as 14 days or more), within 6 months before enrollment, or planning to receive the aforementioned medicines during the study; inhaled and topical steroids are allowed;
  • 14. Have received whole blood, plasma, serum, immunoglobulins, or monoclonal antibodies within 3 months before enrollment, or planning to receive these products during the study;
  • 15. Blood donation or blood loss ≥ 450 mL within 1 month before enrollment, or planning to donate blood during the study;
  • 16. Have received any other vaccine within 30 days before enrollment, or planning to receive any other vaccine within 30 days after the last dose;
  • 17. Currently participating in or planning to participate in other clinical trials during the study;
  • 18. For female participant of : having positive urine pregnancy test, being in pregnancy or lactation before enrollment;
  • 19. Unable to comply with the study procedures or adhere to the study requirements, or there are other conditions that make the participation in this study inappropriate, as determined by the investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Investigational vaccine of Dosage A

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Investigational vaccine of Dosage B

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Investigational vaccine of Dosage C

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Investigational vaccine of Dosage D

    Biological: A zoster mRNA vaccine SYS6017

  • Experimental
    Investigational vaccine of Dosage E

    Biological: A zoster mRNA vaccine SYS6017

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalA zoster mRNA vaccine SYS6017

    SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.

  • OtherPlacebo

    saline solution

06

What researchers measure

Primary outcomes

  1. solicited adverse events

    Time frame: within 14 days post each vaccination

  2. unsolicited adverse events

    Time frame: within 30 days post each vaccination

Secondary outcomes

  1. serious adverse events

    Time frame: from the first vaccination through 12 months post the second vaccination

  2. adverse events of special interest

    Time frame: from the first vaccination through 12 months post the second vaccination

  3. pregnancy events

    Time frame: from the first vaccination through 12 months post the second vaccination

  4. anti-gE antibody geometric mean concentration, geometric mean fold increase and seroconversion rate.

    Time frame: before the second vaccination, 14 and 30 days post the second vaccination

  5. anti-VZV antibody geometric mean titer, geometric mean fold increase and seroconversion rate.

    Time frame: before the second vaccination, 14 and 30 days post the second vaccination

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Dec 2025, 7 months later.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 2, 2025
StartEst.
May 10, 2025
Primary completionEst.
Dec 10, 2025
CompletionEst.
Nov 10, 2026
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06954818
Responsible party
Sponsor
First posted
May 2, 2025
Start date
May 10, 2025 (estimated)
Primary completion
Dec 10, 2025 (estimated)
Completion
Nov 10, 2026 (estimated)
Last update
May 8, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion